Partnering

United Immunity welcomes the opportunity to collaborate with companies and academic institutes interested in using our Myeloid Targeting Platform™ to improve patient health.

We offers its Pullulan nanoparticles (PNPs) and Pullulan coated lipid nanoparticles (P-LNPs) to partners interested in delivering their therapeutic payloads to myeloid cells for cancer and infectious disease vaccines as well as myeloid cell therapeutics, tumor microenvironment modulators, and in vivo CAR-macrophages.

We have a comprehensive and expanding IP portfolio that encompasses the use of PNP, novel PNP and P-LNP compositions, and drug delivery systems targeting DC-SIGN.

Partnership could be in the form of joint research and development collaborations, options, and technology licensing.

We want to provide you with the most important information and services in the best possible way. In order to do this, we need your consent to use the web analysis tool »Google Analytics« to create and evaluate an anonymous analysis of your visit for statistical purposes. You can change your consent at any time on the data protection page, otherwise it will remain valid for twelve months.

Please contact us to learn more: